| 効果 | 増加 |
| 試験方法 | コホート法 |
| 試験期間 | 1-6 ヶ月 |
| 被験者数 | 20 |
| 性別 | 男女 |
| 年齢 | 45-64, 65+ |
| 体型 | 平均 |
Supplementation of N-acetylcysteine at 600mg once daily for ten weeks in persons with stable COPD has resulted in less Eosinophil cationic protein (ECP; indicative of granulocyte breakdown) and less adhesion factors, which are thought to underlie the mucolytic properties and sputum reduction.
Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease
| 効果 | なし |
| 試験方法 | 二重盲検法 |
| 試験期間 | 1-7 日 |
| 被験者数 | 50 |
| 性別 | 男女 |
| 年齢 | 45-64, 65+ |
| 体型 | 肥満, 平均 |
Supplementation of 600mg NAC in persons undergoing exacerbations of COPD symptoms failed to improve any measured symptom or lung function more than placebo.
Effects Of N-acetylcysteine On Outcomes In Chronic Obstructive Pulmonary Disease (Bronchitis Randomized On NAC Cost-Utility Study, BRONCUS): A Randomised Placebo-controlled Trial
| 効果 | なし |
| 試験方法 | 二重盲検法 |
| 試験期間 | 6+ ヶ月 |
| 被験者数 | 523 |
| 性別 | 男女 |
| 年齢 | 45-64, 65+ |
| 体型 | 平均 |
Supplementation of 600mg NAC twice daily over the course of three years in patients with COPD failed to find an attenuation in the rate of lung function deterioration in the whole group, although it appeared that a subcohort of persons not using corticosteroids found benefit.
Long-term Oral N-acetylcysteine Reduces Exhaled Hydrogen Peroxide In Stable COPD
| 効果 | 増加 |
| 試験方法 | 二重盲検法 |
| 試験期間 | 1-6 ヶ月 |
| 被験者数 | 55 |
| 性別 | 男女 |
| 年齢 | 45-64, 65+ |
| 体型 | 肥満 |
Two months supplementation of 600mg NAC twice daily in persons with stable COPD alongside their standard therapy (or placebo with standard therapy) noted that supplementation was able to reduce hydrogen peroxide concentration in the breath, indicating less oxidative stress in lung tissue. The magnitude of reduction was 22-35% and occurred within 15 days.
